Asthma

This is the third indication for the biologic therapy, following its approvals for adult AD and moderate to severe asthma maintenance care.

The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.

What other specialties should become more involved in the network of care for allergic patients?

Is the US population having allergies diagnosed correctly, and are allergies on the rise?

According to investigators, recent trial results indicate no other biologic treatment has shown as rapid onset than benralizumab for patients with eosinophilic asthma.

Investigators sought to evaluate the efficacy, safety, psychosocial impact, quality of life, adherence to and satisfaction with the treatment of dupilumab and add-on treatment.

Pediatric peanut allergy trials have proven successful. Now where do researchers look next?

In this phase 3 study, dupilumab improved outcomes for patients with recurring severe chronic rhinosinusitis with nasal polyps.

What does the typical patient have to treat aside from their allergy, and what are their treatment goals?

Have current guidelines been fitted to consider the future of immunotherapy research?

UNC investigators consider the role current food allergy trials may play in addressing gaps of knowledge on patient individualization.

Investigators conducted a post-hoc analysis in order to assess eosinophil levels and lung function among patients with low FEV1 reversibility to short-acting beta agonists.

Why it may be critical to reassess dosing practices being practiced in investigative food allergy therapies.

About 9 of 10 patients were able to safely consume foods containing peanuts in an eight-year, longitudinal observational study.

Kim and Commins discuss what the next series of data on the investigative peanut immunotherapies may mean for the field.

The therapy was further assessed in asthmatic patients with comorbid chronic rhinosinusitis and with or without nasal polyposis.

UNC School of Medicine colleagues Edwin Kim, MD, MS, and Scott Commins, MD, PhD, explain how the discussion around food allergy care has progressed this year.

This analysis of the phase 3 LIBERTY ASTHMA QUEST study analyzed data for patients with and without allergic rhinitis.

How do current peanut allergy immunotherapies compare, and what other allergens may be addressed next?

Investigative therapy PVX108 showed a favorable tolerability and safety profile in patients with peanut allergies.

How did dupilumab fare in patients with chronic rhinosinusitis with nasal polyps?

Having asthma was associated with sensitization to 1 or more allergens. Having sensitization to the individual allergens—mouse, cockroach, and dust mite—were also associated with sensitization to 1 or more allergens.

Why both physicians and patients need to be on the same page when considering food allergy oral immunotherapy.

In a phase 3 study, dupilumab reduced nasal polyp scores and nasal congestion compared to placebo in patients with chronic rhinosinusitis with nasal polyps.

Why peanut allergy therapies are prioritized in early trials, and how far out are complimentary therapies to the ones currently being investigated.